Table 1.
Demographic characteristics of participants.
| Homologous booster (third dose) | BNT162b2 | mRNA-1273 |
|---|---|---|
| Participants – no. (%) | 58 (46.0 %) | 68 (54.0 %) |
| Age (years) | ||
| Median | 44.5 | 51.2 |
| Inter-quartile range | 35.8–52.5 | 44.1–57.4 |
| Min–max | 23.0–63.0 | 26.5–68.9 |
| Sex – no. (%) | ||
| Female | 40 (69.0 %) | 49 (72.1 %) |
| Male | 18 (31.0 %) | 19 (27.9 %) |
| Previous infection history – no. (%) | 26 (44.8 %) | 35 (51.5 %) |
| Time of booster administration (date) | ||
| Median | 25/11/21 | 03/12/21 |
| Min–max | 08/11/21–14/01/22 | 06/10/21–28/12/21 |
| Time between first and third vaccine dose (days) | ||
| Median | 287 | 288 |
| Inter-quartile range | 273–294 | 285–295 |
| Min-max | 259–332 | 232–313 |
| Total number of blood samples obtained – no. (%) | 202 (48.1 %) | 218 (51.9 %) |